Temasek Holdings Private Ltd Has $662.60 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Temasek Holdings Private Ltd boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,071,180 shares of the medical research company's stock after acquiring an additional 2,813 shares during the period. Thermo Fisher Scientific accounts for about 2.7% of Temasek Holdings Private Ltd's portfolio, making the stock its 12th largest holding. Temasek Holdings Private Ltd owned approximately 0.28% of Thermo Fisher Scientific worth $662,600,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Howard Capital Management Group LLC lifted its stake in Thermo Fisher Scientific by 1.2% in the second quarter. Howard Capital Management Group LLC now owns 54,289 shares of the medical research company's stock worth $30,022,000 after acquiring an additional 632 shares during the last quarter. Sax Wealth Advisors LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth $482,000. QRG Capital Management Inc. lifted its position in Thermo Fisher Scientific by 7.1% in the second quarter. QRG Capital Management Inc. now owns 27,742 shares of the medical research company's stock valued at $15,341,000 after acquiring an additional 1,837 shares during the last quarter. Thrive Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 1.5% in the 2nd quarter. Thrive Wealth Management LLC now owns 3,166 shares of the medical research company's stock valued at $1,751,000 after purchasing an additional 47 shares during the period. Finally, MJP Associates Inc. ADV increased its position in Thermo Fisher Scientific by 4.3% during the second quarter. MJP Associates Inc. ADV now owns 1,753 shares of the medical research company's stock worth $969,000 after buying an additional 72 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on TMO shares. Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They issued a "buy" rating and a $680.00 target price on the stock. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. Royal Bank of Canada reduced their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Bank of America upped their price target on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a "buy" rating in a research note on Monday, September 16th. Finally, Barclays lowered their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating for the company in a report on Wednesday, October 23rd. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average target price of $649.33.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded up $8.78 during trading hours on Friday, reaching $529.64. 587,160 shares of the stock were exchanged, compared to its average volume of 1,526,679. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $202.59 billion, a P/E ratio of 32.65, a P/E/G ratio of 3.59 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $488.02 and a 52 week high of $627.88. The firm has a 50 day simple moving average of $559.78 and a 200-day simple moving average of $576.07.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts' consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the previous year, the firm posted $5.69 earnings per share. Thermo Fisher Scientific's quarterly revenue was up .2% compared to the same quarter last year. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be paid a $0.39 dividend. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific's payout ratio is currently 9.78%.

Thermo Fisher Scientific declared that its board has initiated a stock buyback plan on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its shares are undervalued.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares of the company's stock, valued at approximately $9,333,946.08. The trade was a 1.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the sale, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,175,513.68. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,150 shares of company stock valued at $25,954,465 in the last three months. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.